Compare BELFB & HTFL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | BELFB | HTFL |
|---|---|---|
| Founded | 1949 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.4B |
| IPO Year | N/A | 2025 |
| Metric | BELFB | HTFL |
|---|---|---|
| Price | $210.88 | $30.69 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $164.75 | $39.20 |
| AVG Volume (30 Days) | 156.4K | ★ 832.3K |
| Earning Date | 02-17-2026 | 03-27-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ 19.52 | N/A |
| EPS | ★ 5.17 | N/A |
| Revenue | ★ $649,376,000.00 | $161,881,000.00 |
| Revenue This Year | $28.52 | $40.42 |
| Revenue Next Year | $6.49 | $22.27 |
| P/E Ratio | $40.20 | ★ N/A |
| Revenue Growth | 23.70 | ★ 85.70 |
| 52 Week Low | $58.00 | $25.38 |
| 52 Week High | $214.32 | $41.22 |
| Indicator | BELFB | HTFL |
|---|---|---|
| Relative Strength Index (RSI) | 72.48 | 45.36 |
| Support Level | $193.65 | $30.33 |
| Resistance Level | $214.32 | $32.75 |
| Average True Range (ATR) | 8.00 | 2.05 |
| MACD | 0.96 | -0.44 |
| Stochastic Oscillator | 89.27 | 7.38 |
Bel Fuse Inc designs and manufactures electronic components that protect and connect electronic circuits. Its product portfolio is divided into three categories: magnetic solutions, power solutions & protection, and connectivity solutions. These products are used for the computer, networking, telecommunications, transportation and defense/aerospace, automotive, medical, and consumer electronics industries. Its geographical segments are the United States, Macao, United Kingdom, Slovakia, Germany, Switzerland, and All other foreign countries. Majority of the revenue is derived from United States.
HeartFlow Inc is a commercial-stage medical technology company that has pioneered the use of software and AI to deliver a non-invasive solution for diagnosing and managing coronary artery disease CAD. The company operates and manages its business as one reportable and operating segment, which is the business of non-invasive coronary artery disease detection solutions. Geographically, it operates in United States, United Kingdom, Japan, and Rest of Europe, of which it derives maximum revenue from United States.